Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
Academic Article
- Overview
- Identity
- Additional document info
- View All
Overview
publication date
- June 2017